At a glance
ClinicalIndex Comparison RecordN/ACompleted· 43 enrolled
Drug / intervention
Victoza +2 moredrug
Likely dose
Dapagliflozin 10mg Tabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes
In Brief
A clinical study evaluating Victoza, Placebo, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 43 participants across 1 site.
Detailed Summary
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 before and after administration of liraglutide/placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMay 2016
Primary CompletionDec 2016
Study CompletionDec 2016
TodayJul 2026
First PostedMay 19, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2016
Study CompletionDec 31, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.1 years ago
Interventions
Victozadrug
Single dose of Liraglutide
Placebodrug
Single dose of generic placebo
Dapagliflozin 10mg Tabdrug
single dose of 10 mg dapagliflozin